| Keywords: |
acute granulocytic leukemia; lenalidomide; prednisone; allogeneic stem cell transplantation; clinical trial; doxorubicin; drug efficacy; monotherapy; drug approval; drug targeting; ibritumomab tiuxetan; rituximab; methodology; cyclophosphamide; vincristine; autologous stem cell transplantation; reimbursement; economics; nonhodgkin lymphoma; lymphoma, non-hodgkin; forecasting; neoplasms, second primary; second cancer; radioimmunotherapy; tositumomab i 131; patient referral; myelodysplasia; 5q- syndrome
|
